Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Schering AG begins phase II trials of anticancer compound
The clinical trials will assess ZK-EPO’s safety and efficacy in each of these cancer types. ZK-EPO is the only fully synthetic epothilone in clinical development, and is designed
The clinical trials will assess ZK-EPO’s safety and efficacy in each of these cancer types. ZK-EPO is the only fully synthetic epothilone in clinical development, and is designed
The new collaboration would have involved the continued provision by Discovery of pharmaceutically relevant chemical compounds and hit follow-up libraries for Pfizer’s exclusive use. At the conclusion of
Under the terms of the agreement, Roche will obtain worldwide rights to BCX-4208 in exchange for a $25 million up-front payment and a $5 million payment as reimbursement
Under the terms of the agreement, PIramed will receive an upfront payment and may receive milestone payments during development and on product approval up to a potential $230
Under the agreement, Affitech receives a license to use Xoma’s bacterial cell expression technology for developing antibody products. Affitech also receives an option for the production of antibodies
The patent office undertook a review of the patent in response to a legal challenge to the crystalline form patent for atorvastatin which expires in 2017. The patent
The FDA has also granted orphan drug designation to SGN-40 for chronic lymphocytic leukemia (CLL) providing Seattle Genetics with seven years of marketing exclusivity in the event of
The trial is currently being conducted on Stem Cell Therapeutics’ (SCT) behalf by Danish drug development company Medicon. The trial is designed to characterize the pharmacokinetic profile of
Under the terms of the agreement, Abbott will perform scale-up and GMP manufacturing of TRX4 for use in clinical trials, as well as supply commercial-grade material to support
The first phase II clinical compound, VTP-201227, has a novel mechanism of action and is being developed as a topical agent for the treatment of psoriasis with potential